Search | Clinical Trials Finder

Conditions: Painful Diabetic Neuropathy
Interventions: NRD135SE.1, Placebo; Drug · Other
Lead sponsor: James P. Rathmell, MD; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: San Diego, California • Clermont, Florida • Gainesville, Florida + 18 more

Conditions: Cancer
Interventions: Baseline Participant Assessment, Baseline Healthcare Provider Assessment, Follow-up Participant Assessment, Follow-up Healthcare Provider Assessment, End-of-study Participant Assessment, End-of-study Healthcare Provider Assessment; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumors
Interventions: Indium In-111 pentetreotide; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Miami, Florida • Iowa City, Iowa • New Orleans, Louisiana + 1 more

Conditions: Stroke
Interventions: Stroke Rehabilitation; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Urinary Bladder, Neurogenic
Interventions: Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 18
States / cities: Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more

Conditions: Healthy Volunteers
Interventions: E2086, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Herpes Zoster, Herpes Zoster Vaccine
Interventions: Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 865 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Golden, Colorado • Wichita, Kansas • Columbia, Maryland

Conditions: Avian Influenza, Influenza Immunisation
Interventions: AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 99 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Hypertension, Pulmonary
Interventions: sildenafil, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 24
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more

Conditions: Fabry Disease
Interventions: migalastat HCl 150 mg; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tampa, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Skin Aging
Interventions: Investigational Facial Serum #3, Investigational Facial Serum #1, Investigational Facial Serum #2; Other
Lead sponsor: Victoria Collotta; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 42
States / cities: Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: Questionnaires; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Minutes and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease, Dementias
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis
Interventions: VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more

Conditions: Physical Fitness
Interventions: Equinox Personal Coaching; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 44 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Educational Intervention, Screening Questionnaire Administration, Referral, Questionnaire Administration; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Health-related Quality of Life
Interventions: Vitality Product, Placebo; Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Tucson, Arizona • Chaska, Minnesota • Houston, Texas

Conditions: Gastroesophageal Reflux Disease
Interventions: Dexlansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 35
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 32 more

Conditions: Parkinson Disease, Mild Cognitive Impairment, Old Age; Dementia
Interventions: Adaptango Performance Process (APP) program; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Rett Syndrome
Interventions: TSHA-102; Genetic
Lead sponsor: Taysha Gene Therapies, Inc.; Industry
Eligibility: 2 Years to 3 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more

Conditions: Cancer
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 70 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Search by objective public record fields.

EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

Optimizing Fall-risk Prediction in Older Adults With Cancer

Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors

Video-Based Functional Performance and Assessment Following Stroke

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging, by Comparing to a Placebo

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Geriatric Assessment and Technology Evaluation in Prostate Cancer

Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Equinox Personal Coaching Versus Self-Directed Exercise

Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment

Effects of a Vitality Dietary Supplement on Physical and Mental Function in Middle-aged Adults

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Adaptango Performance PRocess for Older Adults Community reHabilitation

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Frailty Study of Older Adults Getting Chemotherapy and Radiation Therapy

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults